Prospective study and proposal of an outcome predictive nomogram in a consecutive prospective series of differentiated thyroid cancer based on the new ATA risk categories and TNM.

TNM staging system differentiated thyroid cancer persistent or recurrent disease risk stratification system TNM staging and ATA risk stratification systems thyroid cancer outcome thyroid cancer risk factors

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 21 12 2022
accepted: 23 02 2023
medline: 31 3 2023
entrez: 30 3 2023
pubmed: 31 3 2023
Statut: epublish

Résumé

The personalized management of differentiated thyroid cancer (DTC) is currently based on the postoperative TNM staging system and the ATA risk stratification system (RSS), both updated in 2018 and 2015, respectively. We aimed to evaluate the impact of the last two editions of TNM and ATA RSS in the prediction of persistent/recurrent disease in a large series of DTC patients. Our prospective study included 451 patients undergone thyroidectomy for DTC. We classified the patients according to TNM (both VIII and VII ed.) and stratified them according to the ATA RSS (both 2015 and 2009). We then evaluated the response to the initial therapy after 12-18 months according to the ATA "ongoing" risk stratification, and analyzed the variables associated with persistent/recurrent disease by multivariate analysis. The performance of the last two ATA RSSs was not significantly different. By staging patients according to the VIII or VII TNM editions, we found significant differences only in the distribution of patients with structural disease classified in stages III and IV. At multivariate analysis, only T-status and N-status were independently associated with persistent/recurrent disease. Overall, ATA RSSs and TNMs showed low predictive power in terms of persistent/recurrent disease (by Harrell's test). In our series of DTC patients, the new ATA RSS as well as the VIII TNM staging provided no additional benefit compared to the previous editions. Moreover, the VIII TNM staging system may underestimate disease severity in patients with large and numerous lymph node metastases at diagnosis.

Identifiants

pubmed: 36992807
doi: 10.3389/fendo.2023.1128963
pmc: PMC10040819
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1128963

Informations de copyright

Copyright © 2023 Sapuppo, Grasso, Di Benedetto, Belfiore and Pellegriti.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Endocrinol Metab. 2004 Aug;89(8):3713-20
pubmed: 15292295
Thyroid. 2010 Dec;20(12):1341-9
pubmed: 21034228
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22
pubmed: 24557566
Ann Surg Oncol. 2013 Oct;20(11):3477-83
pubmed: 23846784
J Endocrinol Invest. 2017 Dec;40(12):1355-1363
pubmed: 28646475
World J Surg. 2018 Nov;42(11):3624-3631
pubmed: 29750323
Thyroid. 2018 Oct;28(10):1301-1310
pubmed: 30141373
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Eur J Surg Oncol. 2016 Oct;42(10):1491-6
pubmed: 27265038
Medicine (Baltimore). 2017 Jul;96(30):e7575
pubmed: 28746205
J Endocrinol Invest. 2018 Nov;41(11):1349-1353
pubmed: 29549629
CA Cancer J Clin. 2018 Jan;68(1):55-63
pubmed: 29092098
Head Neck. 2016 Apr;38 Suppl 1:E1256-63
pubmed: 26332104
Am J Surg. 2020 Oct;220(4):925-931
pubmed: 32081409
Thyroid. 2017 Sep;27(9):1149-1155
pubmed: 28635571
Thyroid. 2018 Aug;28(8):991-996
pubmed: 29921174
AJNR Am J Neuroradiol. 2013 Sep;34(9):1812-7
pubmed: 23557957
Thyroid. 2012 Nov;22(11):1144-52
pubmed: 23083442
J Cancer Epidemiol. 2013;2013:965212
pubmed: 23737785
Cancer. 2017 Feb 1;123(3):372-381
pubmed: 27741354
Thyroid. 2013 Sep;23(9):1087-98
pubmed: 23402640
Oral Oncol. 2017 Aug;71:81-86
pubmed: 28688696
Cancer Manag Res. 2019 Apr 24;11:3535-3544
pubmed: 31114382
Thyroid. 2018 Feb;28(2):201-209
pubmed: 29256827

Auteurs

Giulia Sapuppo (G)

Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.

Sonia Grasso (S)

Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.

Guenda Di Benedetto (G)

Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.

Antonino Belfiore (A)

Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.

Gabriella Pellegriti (G)

Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.
Researcher in Oncology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH